anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: To evaluate the efficacy and safety of UroBest complex in sachets for combined therapy of patients with acute cystitis in comparison with products of similar composition.
MATERIALS AND METHODS: The randomized multi-center study included 90 patients with acute cystitis aged 18 to 49 years who were treated at the clinical bases of SRC FMBC, FMBA of Russia, Moscow, Russia, Altai State Medical University and Voronezh State Medical University named after N.N. Burdenko. Patients of all groups received Fosfomycin trometamol in a dosage of 3g once, at night. Depending on the additional drug received, they were divided into 3 groups of 30 patients each. In group 1, they took UroBest 1 sachet daily for 7 days from the first day of therapy, NefroBest-N one capsule 2 times a day for 1 month also from the first day of therapy, in combination with UroBest complex in the first week. In group 2, UroBest 1 sachet daily for 7 days was administered, while in group 3, biologically active supplement (BAA) "Uronext" 1 sachet daily for 7 days was given. The study included 4 control points, where the degree and dynamics of changes in laboratory parameters (urinalysis, complete cell count, urine culture with determination of sensitivity to antibiotics), quality of life according to the questionnaire, and pain intensity according to the visual analogue scale (VAS) were assessed, as well as the drug tolerability based on the analysis of adverse events.
RESULTS: The efficacy and safety data were evaluated. Administration of complex preparations with extracts of medicinal plants as an additional to antibacterial therapy led to significant improvement of all parameters, except for the level of leucocytes in the complete cell count. The most pronounced improvement was observed in groups 1, and lesser improvement was noted in group 2. One patient in group 3 had an adverse event, which was resolved spontaneously.
CONCLUSION: UroBest has a favorable efficacy and safety profile. According to our experience, combination of UroBest and NefroBest-N complexes leads to more pronounced positive changes in laboratory parameters and patient's condition according to the questionnaires compared to UroBest as monotherapy and, to an even greater extent, to the biologically active supplement UroNext.
An electroporation buffer comprising: a solvent; a sugar; a chloride salt; and a buffering agent. In certain embodiments: the solvent is water; the sugar is glucose or mannitol; the chloride salt is potassium chloride (KCl) or magnesium chloride (MgCl 2 ); and the buffering agent is sodium phosphate, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and/or dimethyl sulfoxide (DMSO). A method of electroporation, the method comprising applying an electric current to a suspension comprising: isolated eukaryotic cells; a biological material that is exogenous to the cells; and the aforementioned buffer. A recombinant cell produced using such a method. An electroporation apparatus comprising: one or more chambers; one or more pairs of electrodes configured to generate electric fields within the one or more chambers, wherein each electric field corresponds to one chamber; and a flow channel. A method for electroporation comprising utilizing the aforementioned electroporation apparatus.
Following pathological confirmation on of lung ADC, patients will proceed with TTFields treatment. The NovoTTF-200T System is an investigational medical device delivering 150 kHz TTFields to the patient's chest. The device is applied continuously for an average duration of 18 hours per day for 3 weeks (+/- 1 week).
~-androsten-4-OL-3.17-dione, does not prevent testosterone-Estrogen is an active neuroprotectant and is presently investi-~~ mediated neuroprotection. In contrast, anti-androgen, flutamide, gated as a potential therapy against Alzheimer's disease~~ eliminates testosterone-mediated neuroprotection. Testoster-for women. To determine if male hormones could also be~~~ one analog, methyltestosterone, showed androgen receptor-neuroprotective, we investigated the effect of testosterone,~~ dependent neuroprotection that was delayed in time indicating methyltestosterone, and epitestosterone at physiological con-~~ that a metabolite may be the active agent. The endogenous centrations on primary cultures of human neurons induced to~~ anti-androgen, epitestosterone, also showed a slight neuro-undergo apoptosis by serum deprivation. Serum deprivation~~ protective effect but not through the androgen receptor. These significantly induces neuronal apoptosis in a protracted~~ results indicate that androgens induce neuroprotection directly fashion. As expected, physiological concentrations of 17-.beta.-~ through the androgen receptor. These data suggest that andro-estradiol and transcriptionally inactive 17-.alpha.-estradiol protect~ gens may also be of therapeutic value against Alzheimer's neurons against apoptosis. Similar to 17-.beta.-estradiol, physio-~ disease in aging males. logical concentrations of testosterone are also neuroprotec-tive. Androgen receptors are present at 8 ~ 2 fmoles/mg~~~  protein in the neuron cultures. The non-aromatizable androgen,~~  mibolerone, is also neuroprotective and aromatase inhibitor,
The invention pertains to the Chinese medicine field and relates to a plaster of external use for curing facial palsy and a preparation method thereof. The plaster of the invention is made from 27 Chinese medicinal herbs such as giant typhonium rhizome, seed of nuxvomica poison nut, stiff silkworm, unprocessed Sichuan aconite root, unprocessed kusnezoff monkshood root, saffron, divaricate saposhnikovia root, croton seed, peach seed, medicinal cyathula root, etc. The plaster of the invention is made based on a secret recipe handed down from generation to generation of the inventor and combines clinical experiences over the years after repeated experiments; therefore, the plaster has special curative effect to obstinate facial paralysis. The combination method of the invention is properly, precisely and uniquely prepared. By adopting the plaster of the invention, the diseases such as slanting eyes and mouth caused by the facial paralysis, facial spasm, etc. can be fast cured with short curing course, high cure rate and low cost. The plaster of the invention also has specific effect on rheumatoid arthritis, lumbocrural pain, trigeminal neuralgia and parotitis.
Children aged 0.5-10 years presenting at health centres with fever or history of fever and other symptoms suggestive of malaria will be screened; children found to have uncomplicated Plasmodium falciparum malaria will be randomized to receive treatment with AS/AQ, SP/AQ or SP/CQ. A drug dispenser will supervise the first dose of medication and subsequent doses will be given to the child's parent to be administered at home, unsupervised by the study team. Patients will be visited at home three days later. Unused medication will be counted and the mother will be asked about the number of doses the child received and any side effects. Children will be seen again 2 and 4 weeks after treatment to collect finger prick samples for packed cell volume (PCV) and malaria microscopy. The primary endpoint is clinical failure by day 28. Analysis will be by intention to treat.
Group B had no exercise in the first 6 weeks and then underwent interactive video game-based exercise training in the subsequent 6 weeks. The exercise program consisted of 30-minute sessions 3 times per week for 6 weeks. Outcomes were measured at weeks 0, 6, and 12.
Nuclear factor of activated T cells 5 (NFAT5; also called TonEBP/OREBP) is a transcription factor that is activated by hypertonicity and induces osmoprotective genes to protect cells against hypertonic conditions. In the kidney, renal tubular NFAT5 is known to be involved in the urine concentration mechanism. Previous studies have suggested that NFAT5 modulates the immune system and exerts various effects on organ damage, depending on organ and disease states. Pathophysiological roles of NFAT5 in renal tubular cells, however, still remain obscure. We conducted comprehensive analysis by performing transcription start site (TSS) sequencing on the kidney of inducible and renal tubular cell-specific NFAT5 knockout (KO) mice. Mice were subjected to unilateral ureteral obstruction to examine the relevance of renal tubular NFAT5 in renal fibrosis. TSS sequencing analysis identified 722 downregulated TSSs and 1,360 upregulated TSSs, which were differentially regulated ≤-1.0 and ≥1.0 in log2 fold, respectively. Those TSSs were annotated to 532 downregulated genes and 944 upregulated genes, respectively. Motif analysis showed that sequences that possibly bind to NFAT5 were enriched in TSSs of downregulated genes. Gene Ontology analysis with the upregulated genes suggested disorder of innate and adaptive immune systems in the kidney. Unilateral ureteral obstruction significantly exacerbated renal fibrosis in the renal medulla in KO mice compared with wild-type mice, accompanied by enhanced activation of immune responses. In conclusion, NFAT5 in renal tubules could have pathophysiological roles in renal fibrosis through modulating innate and adaptive immune systems in the kidney.NEW & NOTEWORTHY TSS-Seq analysis of the kidney from renal tubular cell-specific NFAT5 KO mice uncovered novel genes that are possibly regulated by NFAT5 in the kidney under physiological conditions. The study further implied disorders of innate and adaptive immune systems in NFAT5 KO mice, thereby exacerbating renal fibrosis at pathological states. Our results may implicate the involvement of renal tubular NFAT5 in the progression of renal fibrosis. Further studies would be worthwhile for the development of novel therapy to treat chronic kidney disease.
The aim of the study is to clarify whether follow-up of cell changes is carried out with sufficiently good quality. It is nationally recommended to perform an HPV test on mild cell changes and only refer to clinical follow-up if you are HPV positive. Descriptive statistics on HPV-testing and follow-up of quality are not available today. If HPV testing has not already been performed, archived samples with glandular cell changes will be HPV-analyzed in Cobas 4800 HPV-polymerase chain reaction (PCR), which shows data on the presence of HPV and Luminex-PCR, which shows which HPV types the samples have. Women with low-grade squamous cell changes (ASCUS and CIN1) with simultaneous HPV analysis will be followed up with data from the Swedish National Cervical Screening Registry (NKCx) from the last ten years. A register linkage with data from NKCx and the National Cancer Registry at the National Board of Health and Welfare will be carried out to determine which women have developed gynecological cancer, cervical cancer and/or pre-cancer (cancer in situ). A follow-up review of reported original cytological (cell samples) and histological (tissue samples) diagnoses will be performed by cytodiagnostics and cytopathologists, to verify the correct diagnosis.

Statistics on collection of non-organized cell samples after a partial negative sample where follow-up is not recommended are produced in aggregated form in the form of an extract from NKCx
INTRODUCTION: Hypercapnia is developed in patients with acute and/or chronic respiratory conditions. Clinical data concerning hypercapnia and respiratory infections interaction is limited.
AREAS COVERED: Currently, the relationship between hypercapnia and respiratory infections remains unclear. In this review, we summarize studies on the effects of hypercapnia on models of pulmonary infections to clarify the role of elevated CO2 in these pulmonary pathologies. Hypercapnia affects different cell types in the alveoli, leading to changes in the immune response. In vitro studies show that hypercapnia downregulates the NF-κβ pathway, reduces inflammation and impairs epithelial wound healing. While in vivo models show a dual role between short- and long-term effects of hypercapnia on lung infection. However, it is still controversial whether the effects observed under hypercapnia are pH dependent or not.
EXPERT OPINION: The role of hypercapnia is still a controversial debate. Hypercapnia could play a beneficial role in mechanically ventilated models, by lowering the inflammation produced by the stretch condition. But it could be detrimental in infectious scenarios, causing phagocyte dysfunction and lack of infection control. Further data concerning hypercapnia on respiratory infections is needed to elucidate this interaction.
FIELD: cosmetics. SUBSTANCE: invention relates to ready for using composition for keratin fibers oxidative composite and, in part, human keratin fibers, for example, hair. Composite comprises at least one oxidizing agent, at least one enzymatic system where enzyme relating to class of two- or tetra-electronic oxidoreductase or peroxidase is immobilized on material matrix obtaining by method "sol-gel" in medium suitable for staining. Invention relates also to method of staining using this composition. EFFECT: strongly staining agent with enhanced thermal stability. 41 cl
In controlled trials, clinically relevant changes in standard laboratory test parameters were rarely associated with administration of Micardis® HCT (telmisartan and hydrochlorothiazide) tablets.

Hemoglobin and Hematocrit: Decreases in hemoglobin (≥ 2 g/dL) and hematocrit (≥ 9%) were observed in 1.2% and 0.6% of telmisartan/hydrochlorothiazide patients, respectively, in controlled trials. Changes in hemoglobin and hematocrit were not considered clinically significant and there were no discontinuations due to anemia.

Creatinine, Blood Urea Nitrogen (BUN): Increases in BUN (≥ 11.2 mg/dL) and serum creatinine (≥ 0.5 mg/dL) were observed in 2.8% and 1.4%, respectively, of patients with essential hypertension treated with MICARDIS HCT tablets in controlled trials. No patient discontinued treatment with MICARDIS HCT tablets due to an increase in BUN or creatinine.

Liver Function Tests: Occasional elevations of liver enzymes and/or serum bilirubin have occurred. No telmisartan/hydrochlorothiazide treated patients discontinued therapy due to abnormal hepatic function.

Serum Electrolytes: See PRECAUTIONS.
Empirical studies from laboratory systems and humans show that the gut microbiota is linked to host health. Similar evidence for effects on traits linked to fitness in nature is rare, not least because experimentally manipulating the gut microbiota is challenging. We isolated, characterized, and cultured a bacterial strain, Lactobacillus kimchicus APC4233, directly from a wild bird (the great tit Parus major) and provided it as a self-administered dietary supplement. We assessed the impact of the treatment on the host microbiota community, on weight, and tested whether the treatment affected a previous result linking microbiota alpha diversity to weight in nestlings. The treatment dramatically increased L. kimchicus abundance in the gut microbiota and increased alpha diversity. This effect was strongest in the youngest birds, validating earlier findings pointing to a brief developmental window when the gut microbiota are most sensitive. In time-lagged models, nestling weight was higher in the treatment birds suggesting L. kimchicus may have probiotic potential. There was also a positive time-lagged relationship between diversity and weight in control birds but not in the treatment birds, suggesting L. kimchicus helped birds compensate for low alpha diversity. We discuss why ecological context is likely key when predicting impacts of the microbiome. The manipulation of the gut microbiota with a host native strain in this wild population provides direct evidence for the role of the microbiota in the ecology and evolution of natural populations.
This condition included all BCT applied in the planning and self-efficacy arms. The intervention was integrated into health promotion-nutrition education program. The intervention was applied twice (the baseline and 2-month follow-up).
The present invention discloses one coding gene of rotavirus VP6 protein and its application, and aims at providing one coding gene of rotavirus VP6 protein with high expression amount in dicotyledonous plant, especially clover, method of producing oral rotavirus vaccine with the coding gene and the obtained oral vaccine. The rotavirus VP6 protein coding gene has one of the following nucleotide sequences: 1. DNA sequence of SEQ ID No. 1 in the sequence list; 2. DNA sequence of SEQ ID No. 2 in the sequence list; 3. the nucleotide sequence capable of hybridizing in high strict condition with the DNA sequence limited by SEQ ID No. 1 or SEQ ID No. 2; and 4. DNA sequence possessing over 80 % homology with the SEQ ID No. 1 or SEQ ID No. 2 limited DNA sequence and high expression amount in dicotyledonous plant. The oral rotavirus vaccine is used in preventing various rotavirus infection caused acute diarrhea of infant and young animal.
<P>PROBLEM TO BE SOLVED: To provide an Epstein-Barr Virus (EBV)-specific polypeptide useful for immunodiagnosis and immunotherapy of EBV-associated diseases.  <P>SOLUTION: The polypeptide is a polypeptide consisting of a specific amino acid sequence and capable of binding to an antibody in specimens from individuals with the EBV-associated diseases. A method for detecting the antibody to the polypeptide comprises contacting the specimens to the polypeptide and confirming whether the antibody binds to the peptide. A drug composition contains these polypeptides. Conservative variants and their mixtures of the polypeptides are provided.  <P>COPYRIGHT: (C)2004,JPO
Participants will be asked to fill out questionnaires/surveys and health measures will be collected throughout the study visit. These health measures will include: blood pressure, heart rate, height/weight, waist circumference, percent body fat, resting metabolic rate, and salivary cortisol. Breakfast will be provided and then a 40-minute game of Monopoly™ will be played, and lunch will be provided after the game. Participants will be given an accelerometer to measure movements, and a food diary to be used for a 24-hour period. Once the 24-hour monitoring period has been completed, the participants will be finished with the study activities. The accelerometer and food diary will be returned by either bringing them to the investigators or mailing the items back to the investigators.
During a 240 minute hyperglycemic clamp, subjects will have (after 90 minutes of the clamp) GIP infused at 4 incremental dosages, (initial dose will be 2.0 ng/kg/min, followed by 4.0, 8.0, and 16.0 ng/kg/min). Each dose will be infused continuously for 30 minutes, followed immediately by the next higher dose. The total time of this procedure is 240 minutes.
BACKGROUND: Mutations in ANO3 are a rare cause of autosomal dominant isolated or combined dystonia, mainly presenting in adulthood.
CASES: We extensively characterize a new, large ANO3 family with six affected carriers. The proband is a young girl who had suffered from tremor and painful dystonic movements in her right arm since the age of 11 years. She later developed a diffuse dystonic tremor and mild extrapyramidal signs (ie, rigidity and hypodiadochokinesis) in her right arm. She also suffered from psychomotor delay and learning difficulties. Repeated structural and functional neuroimaging were unremarkable. A dystonic tremor was also present in her two sisters. Her paternal aunt, father, and a third older sister presented episodic postural tremor in the arms. The father and one sister also presented learning difficulties. The heterozygous p.G6V variant in ANO3 was identified in all affected subjects.
LITERATURE REVIEW: Stratification by age at onset divided ANO3 cases into two major groups, where younger patients displayed a more severe phenotype, probably due to variants near the scrambling domain.
CONCLUSIONS: We describe the phenotype of a new ANO3 family and highlight the need for functional studies to explore the impact of ANO3 variants on its phospholipid scrambling activity.
Approximately 200 healthy volunteers recruited. They complete a brief demographic survey and a undergo one-time buccal swab for collection of cheek cells for DNA analysis.
This article presents a comprehensive analysis of microvascular decompression (MVD) surgery as a treatment option for hemifacial spasm (HFS). Beginning with a thorough literature review, it explores the historical context, prevalence, and underlying mechanisms of HFS, laying a robust foundation for discussing MVD. Various surgical techniques, from traditional microscopic to fully endoscopic approaches, are described, along with their procedural nuances and advantages. Clinical data, including patient demographics and surgical success rates, substantiate the efficacy of MVD in alleviating HFS symptoms. The discussion of postoperative complications provides valuable insights into practical challenges. However, limitations such as single-center design, lack of robust statistical analysis, and absence of comparative data between endoscopic and microscopic approaches diminish the article's potential impact. Recommendations for multicenter collaborations, enhanced statistical analyses, comparative studies, and discussions on surgical training could significantly enhance the article's contribution to neurosurgery practice.
BACKGROUND: NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels are variably elevated in heart failure with preserved ejection fraction (HFpEF), even in the presence of increased left ventricular filling pressures. NT-proBNP levels are prognostic in HFpEF and have been used as an inclusion criterion for several recent randomized clinical trials. However, the underlying biologic differences between HFpEF participants with high and low NT-proBNP levels remain to be fully understood.
METHODS: We measured 4928 proteins using an aptamer-based proteomic assay (SOMAScan) in available plasma samples from 2 cohorts: (1) Participants with HFpEF enrolled in the PHFS (Penn Heart Failure Study; n=253); (2) TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) participants in the Americas (n=218). We assessed the relationship between SOMAScan-derived plasma NT-proBNP and levels of other proteins available in the SOMAScan assay version 4 using robust linear regression, with correction for multiple comparisons, followed by pathway analysis.
RESULTS: NT-proBNP levels exhibited prominent proteome-wide associations in PHFS and TOPCAT cohorts. Proteins most strongly associated with NT-proBNP in both cohorts included SVEP1 (sushi, von Willebrand factor type-A, epidermal growth factor, and pentraxin domain containing 1; βTOPCAT=0.539; P<0.0001; βPHFS=0.516; P<0.0001) and ANGPT2 (angiopoietin 2; βTOPCAT=0.571; P<0.0001; βPHFS=0.459; P<0.0001). Canonical pathway analysis demonstrated consistent associations with multiple pathways related to fibrosis and inflammation. These included hepatic fibrosis and inhibition of matrix metalloproteases. Analyses using cut points corresponding to estimated quantitative concentrations of 360 pg/mL (and 480 pg/mL in atrial fibrillation) revealed similar proteomic associations.
CONCLUSIONS: Circulating NT-proBNP levels exhibit prominent proteomic associations in HFpEF. Our findings suggest that higher NT-proBNP levels in HFpEF are a marker of fibrosis and inflammation. These findings will aid the interpretation of NT-proBNP levels in HFpEF and may guide the selection of participants in future HFpEF clinical trials.